HER2 genomic alterations are identified as a primary or acquired resistance mechanism to first generation EGFR TKI (erlotinib) and second generation EGFR TKI (afatinib) in NSCLC.95 This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.